ALIM (Alimera Sciences, Inc.) Company Cash Volume

ALIM (Alimera Sciences) - company brandmark

Alimera Sciences (ALIM) maintains its position in the diabetic macular edema therapy segment thanks to robust patent protection. The business focuses on ophthalmology centers, benefiting from the global increase in the number of diabetics. Cost optimization is achieved through the outsourcing of production and logistics. The cash volume trend clearly demonstrates the issuer's liquidity, with the latest parameter standing at 0.01.

alimerasciences.com - ALIM Company Cash Balance (period 07/04/2022 - 09/21/2024)

Metric breakdowns and analytics for Alimera Sciences (ALIM)

- stock value and consensus price forecast:
- business market valuation indicators:
Basic company analysis:Alimera Sciences, Inc.
Brand item of Alimera

The high margins of the drug Iluvien directly determine the current cash position of Alimera Sciences (ALIM). This indicator aggregates all cash and cash equivalents, reflecting the issuer's total liquidity. The calculation identifies excess capital which, in the absence of investment, reduces overall business profitability. A steady operational free cash flow (FCF) ensures the consistent growth of this metric. Monitoring these balances confirms the company's financial stability.